[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NL1037721C2 - AXIALLY CUT-OUT TUBE THROUGH THROUGH A CRIMPING COUSER OR OTHERWISE ON AN INJECTION SYRINGE, THE CONTENT OF WHICH IS NOT VISIBLE AND THE INFLUENCE OF LIGHT AND SUCH MEDICATION ARE PREVENTED. - Google Patents

AXIALLY CUT-OUT TUBE THROUGH THROUGH A CRIMPING COUSER OR OTHERWISE ON AN INJECTION SYRINGE, THE CONTENT OF WHICH IS NOT VISIBLE AND THE INFLUENCE OF LIGHT AND SUCH MEDICATION ARE PREVENTED. Download PDF

Info

Publication number
NL1037721C2
NL1037721C2 NL1037721A NL1037721A NL1037721C2 NL 1037721 C2 NL1037721 C2 NL 1037721C2 NL 1037721 A NL1037721 A NL 1037721A NL 1037721 A NL1037721 A NL 1037721A NL 1037721 C2 NL1037721 C2 NL 1037721C2
Authority
NL
Netherlands
Prior art keywords
medication
light
visible
influence
prevented
Prior art date
Application number
NL1037721A
Other languages
Dutch (nl)
Inventor
Jan Willem Popma
Original Assignee
Jan Willem Popma
Popma Partners Beheer B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jan Willem Popma, Popma Partners Beheer B V filed Critical Jan Willem Popma
Priority to NL1037721A priority Critical patent/NL1037721C2/en
Application granted granted Critical
Publication of NL1037721C2 publication Critical patent/NL1037721C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/3129—Syringe barrels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Description

Axiaal doorgesneden buis welke door middel van een krimpkous of anderszins om een injectiespuit wordt aangebracht waardoor de inhoud daarvan niet zichtbaar is en de invloed van licht en dergelijke op de medicatie wordt voorkomen.Axially cut tube which is fitted around a syringe by means of a heat shrink or otherwise, as a result of which the contents thereof are not visible and the influence of light and the like on the medication is prevented.

_ De hierboven beschreven afscherming van de inhoud van een injectiespuit is van belang 0 bij dubbelblinde onderzoeken zodat zowel de toediener als de patiënt niet kunnen waarnemen of daadwerkelijk de medicatie dan wel een placebo of anderszins wordt ingespoten.The shielding of the contents of a syringe described above is important in double-blind examinations so that both the operator and the patient cannot see whether the medication or a placebo or otherwise is being injected.

10 1 Bovendien is de afscherming van de inhoud van belang bij medicaties die gevoelig zijn voor licht en dergelijke waardoor een langere tijd beschikbaar is tussen de productie en de toediening hetgeen sterke kostenbesparingen met zich meebrengt.In addition, the shielding of the content is important for medications that are sensitive to light and the like, whereby a longer time is available between production and administration, which entails considerable cost savings.

10377211037721

Claims (2)

1. Bij dubbelblinde onderzoeken wordt de inhoud van de injectiespuit zodanig afgeschermd dat zowel de toediener als de patiënt niet kunnen waarnemen of daadwerkelijk de medicatie dan wel een placebo of anderszins wordt ingespoten;1. In double-blind studies, the contents of the syringe are shielded in such a way that both the operator and the patient cannot see whether the medication or a placebo or otherwise is being injected; 2. Bij medicaties die gevoelig zijn voor licht en dergelijke kan de tijd tussen de productie en de toediening ervan verlengd worden hetgeen sterke kostenbesparingen met zich meebrengt. 10377212. With medication that are sensitive to light and the like, the time between production and administration can be extended, which entails significant cost savings. 1037721
NL1037721A 2010-02-16 2010-02-16 AXIALLY CUT-OUT TUBE THROUGH THROUGH A CRIMPING COUSER OR OTHERWISE ON AN INJECTION SYRINGE, THE CONTENT OF WHICH IS NOT VISIBLE AND THE INFLUENCE OF LIGHT AND SUCH MEDICATION ARE PREVENTED. NL1037721C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NL1037721A NL1037721C2 (en) 2010-02-16 2010-02-16 AXIALLY CUT-OUT TUBE THROUGH THROUGH A CRIMPING COUSER OR OTHERWISE ON AN INJECTION SYRINGE, THE CONTENT OF WHICH IS NOT VISIBLE AND THE INFLUENCE OF LIGHT AND SUCH MEDICATION ARE PREVENTED.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1037721 2010-02-16
NL1037721A NL1037721C2 (en) 2010-02-16 2010-02-16 AXIALLY CUT-OUT TUBE THROUGH THROUGH A CRIMPING COUSER OR OTHERWISE ON AN INJECTION SYRINGE, THE CONTENT OF WHICH IS NOT VISIBLE AND THE INFLUENCE OF LIGHT AND SUCH MEDICATION ARE PREVENTED.

Publications (1)

Publication Number Publication Date
NL1037721C2 true NL1037721C2 (en) 2011-08-17

Family

ID=42801074

Family Applications (1)

Application Number Title Priority Date Filing Date
NL1037721A NL1037721C2 (en) 2010-02-16 2010-02-16 AXIALLY CUT-OUT TUBE THROUGH THROUGH A CRIMPING COUSER OR OTHERWISE ON AN INJECTION SYRINGE, THE CONTENT OF WHICH IS NOT VISIBLE AND THE INFLUENCE OF LIGHT AND SUCH MEDICATION ARE PREVENTED.

Country Status (1)

Country Link
NL (1) NL1037721C2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4048997A (en) * 1976-11-01 1977-09-20 Mpl, Inc. Syringe with actinic radiation protection
KR20040012189A (en) * 2002-08-01 2004-02-11 소광섭 Syringe for shading liquid therein from light
WO2007067653A2 (en) * 2005-12-05 2007-06-14 Lifeline Cell Technology Cell culture medium container assembly

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4048997A (en) * 1976-11-01 1977-09-20 Mpl, Inc. Syringe with actinic radiation protection
KR20040012189A (en) * 2002-08-01 2004-02-11 소광섭 Syringe for shading liquid therein from light
WO2007067653A2 (en) * 2005-12-05 2007-06-14 Lifeline Cell Technology Cell culture medium container assembly

Similar Documents

Publication Publication Date Title
NL1037721C2 (en) AXIALLY CUT-OUT TUBE THROUGH THROUGH A CRIMPING COUSER OR OTHERWISE ON AN INJECTION SYRINGE, THE CONTENT OF WHICH IS NOT VISIBLE AND THE INFLUENCE OF LIGHT AND SUCH MEDICATION ARE PREVENTED.
Habibzadeh et al. Effect of applying checklist on quality of intra-hospital transport of intensive care patients
Reddy et al. First Formal Analysis of the “ASA Plavix Registry”(ASAP): Watchman Left Atrial Appendage Closure in Atrial Fibrillation Patients With Contradication to Oral Anticoagulation
Ansari Moghaddam et al. Investigating the effects of magnesium oxide nanoparticle toxicity on K562 blood type cancer cells
Basu et al. Curcumin, anti-oxidant, and pioglitazone therapy with inclusion of vitamin e in non-alcoholic fatty liver disease-a randomized open label placebo controlled clinical prospective trial (captive)
Kotecki et al. Update of the T-DIS randomized phase II trial: Trabectedin rechallenge versus continuation in patients (pts) with advanced soft tissue sarcoma (ASTS)
Zhang et al. Phase 3 efficacy results of a single dose of NEPA, a fixed combination of netupitant and palonosetron, versus a 3-day regimen of aprepitant/granisetron (APR/GRAN) for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients
Esmaeili Nasrabadi et al. Impacts of COVID-19 Pandemic: Phthalate Esters Released from Face Masks and its Associated Exposure Risk
Missri et al. 22P Toxicity profile of immune and non-immune therapies in phase I/II trials: A comprehensive longitudinal analysis
Jain et al. The comparison of efficacy of ursodeoxycholic acid, ondandsetron and natrexone in the prupitus or acute cholestatic viral hepatitis
Dhangar et al. Formulation and Evaluation of Proniosomal Gel in Ocular Drug
Bancroft Governments and insulin: Overcoming barriers to fulfilling the right to an essential medicine
Hajizadeh Moghaddam et al. Neuroprotective effect of Quince leaf hydroalcoholic extract on intracerebroventricular streptozotocin-induced oxidative stress in cortical tissue of rat brain
برکتين et al. Adherence of treatment of schizophrenia to the published treatment guidelines in university hospital
Berardo et al. Cold ischemic injury is reduced by the mGluR5 negative allosteric modulator MPEP in rat livers from cardiac death donors
CN203302550U (en) Vacuum seal cosmetic bottle
Pankaj et al. Drug Approval Process: A Contrastive Approach
Wu et al. Mechanisms of wavebreak during KATP channel activation in isolated rabbit heart
Assaraf et al. Neurological Impairment in Cirrhotic Patients Admitted to ICU: Hepatic Versus Drug-Induced Encephalopathy
Benson et al. O-007 Neuropilin 1 (NRP1) may be prognostic and identify a subgroup of Patients with Metastatic Colorectal Cancer (mCRC) who Benefit from Tivozanib+ mFOLFOX6 compared to Bevacizumab+ mFOLFOX6
Singh et al. Possible role of ATP-sensitive potassium and MPTP channels in pharmacological postconditioning in mouse brain
Grothey et al. Phase III Randomized, Placebo (Pl)-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium (CaMg) to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (sNT), N08CB: an Alliance for Clinical Trials in Oncology Study1
Camilleri et al. Comparison of post-authorisation requirements between regulatory agencies for medicinal products
requires Kayexalate drug interaction studies
Moreira et al. Effect of eslicarbazepine acetate on cognition in children with epilepsy

Legal Events

Date Code Title Description
MM Lapsed because of non-payment of the annual fee

Effective date: 20160301